<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To characterize <z:hpo ids='HP_0006733'>acute megakaryocytic leukemia</z:hpo> (<z:e sem="disease" ids="C0023462" disease_type="Neoplastic Process" abbrv="">FAB M7</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), we identified 37 patients with M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated at M.D </plain></SENT>
<SENT sid="1" pm="."><plain>Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated during the same period </plain></SENT>
<SENT sid="2" pm="."><plain>The median age of the M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorder</z:e> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or both, and 7 patients (19%) had previously received chemotherapy for other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Extensive bone marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> was found in 23 patients (62%) </plain></SENT>
<SENT sid="4" pm="."><plain>Poor cytogenetic characteristics were observed in 49% of patients with M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> versus 33% of others (P &lt; .001) </plain></SENT>
<SENT sid="5" pm="."><plain>Complete remission rates were 43% with M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 57% with non-M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P = .089) </plain></SENT>
<SENT sid="6" pm="."><plain>Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006) </plain></SENT>
<SENT sid="7" pm="."><plain>Median disease-free survivals were 23 versus 52 weeks, respectively (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>By multivariate analysis, M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049) </plain></SENT>
<SENT sid="9" pm="."><plain>These results confirm the poor prognosis of M7 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease </plain></SENT>
</text></document>